Barrington Research reaffirmed their buy rating on shares of Opko Health (NASDAQ:OPK) in a research report report published on Monday morning. They currently have a $7.00 price objective on the biotechnology company’s stock. Barrington Research also issued estimates for Opko Health’s FY2018 earnings at ($0.20) EPS, Q1 2019 earnings at ($0.05) EPS, Q2 2019 earnings at ($0.04) EPS, Q3 2019 earnings at ($0.04) EPS, FY2019 earnings at ($0.17) EPS, FY2020 earnings at ($0.02) EPS, FY2021 earnings at $0.11 EPS and FY2022 earnings at $0.31 EPS.

“We are maintaining our OUTPERFORM investment rating on OPK shares and our price target remains $7. We arrive at our price target via a DCF methodology for its current commercial business plus the hGH-CTP program. We assign an additional $1 of value for the rest of OPKO’s product pipeline.”,” Barrington Research’s analyst wrote.

A number of other research firms have also weighed in on OPK. BidaskClub upgraded shares of Opko Health from a buy rating to a strong-buy rating in a research report on Friday, August 3rd. ValuEngine upgraded shares of Opko Health from a sell rating to a hold rating in a research report on Thursday, July 26th. Finally, Cantor Fitzgerald restated a buy rating and set a $20.00 price target on shares of Opko Health in a research report on Tuesday, August 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Opko Health presently has a consensus rating of Hold and a consensus target price of $9.69.

OPK stock opened at $3.23 on Monday. The stock has a market cap of $2.09 billion, a PE ratio of -11.14 and a beta of 1.89. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.91 and a quick ratio of 0.90. Opko Health has a 52 week low of $2.66 and a 52 week high of $6.40.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The firm had revenue of $250.00 million for the quarter, compared to analyst estimates of $264.04 million. Opko Health had a negative net margin of 30.24% and a negative return on equity of 8.68%. Opko Health’s quarterly revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.08) earnings per share. As a group, equities analysts anticipate that Opko Health will post -0.23 EPS for the current fiscal year.

In other news, CEO Phillip Md Et Al Frost bought 5,000 shares of the firm’s stock in a transaction on Thursday, August 30th. The shares were bought at an average cost of $5.90 per share, for a total transaction of $29,500.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $18,106,810.90. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired a total of 55,000 shares of company stock worth $313,000 over the last quarter. 42.74% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the business. Wells Fargo & Company MN raised its stake in shares of Opko Health by 10.1% in the 1st quarter. Wells Fargo & Company MN now owns 537,283 shares of the biotechnology company’s stock valued at $1,703,000 after acquiring an additional 49,320 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Opko Health by 17,876.0% in the 1st quarter. Russell Investments Group Ltd. now owns 110,013 shares of the biotechnology company’s stock valued at $349,000 after acquiring an additional 109,401 shares during the period. Millennium Management LLC raised its stake in shares of Opko Health by 95.6% in the 1st quarter. Millennium Management LLC now owns 2,178,877 shares of the biotechnology company’s stock valued at $6,907,000 after acquiring an additional 1,065,216 shares during the period. Xact Kapitalforvaltning AB raised its stake in shares of Opko Health by 58.2% in the 1st quarter. Xact Kapitalforvaltning AB now owns 57,921 shares of the biotechnology company’s stock valued at $184,000 after acquiring an additional 21,300 shares during the period. Finally, Essex Investment Management Co. LLC raised its stake in shares of Opko Health by 3.5% in the 2nd quarter. Essex Investment Management Co. LLC now owns 285,700 shares of the biotechnology company’s stock valued at $1,343,000 after acquiring an additional 9,697 shares during the period. Institutional investors own 24.87% of the company’s stock.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Further Reading: What is Cost of Debt?

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.